Recent Progress on Genetic Diagnosis and Therapy for β-Thalassemia in China and Around the World
Overview
Authors
Affiliations
Thalassemia is a recessive monogenic hematological disease associated with reduced amounts of functional hemoglobin caused by mutations/deletions in at least one of the globin genes. This disease has attracted significant attention throughout the years in terms of genetic diagnosis and developments in gene and cell therapy. Here, recent progress is reviewed in the genetic diagnosis and development of therapeutics for thalassemia, particularly β-thalassemia, in China and around the world.
Hu J, Song Z, Zhao L, Chavarria Gonzalez S, Wang E, Hou X J Glob Health. 2024; 14:04073.
PMID: 38779874 PMC: 11112532. DOI: 10.7189/jogh.14.04073.
Chi Y, Yang G, Guo C, Zhang S, Hong L, Tang H Life (Basel). 2023; 13(11).
PMID: 38004297 PMC: 10671877. DOI: 10.3390/life13112157.
Development and clinical translation of gene therapy.
Wu X, He X, Liu F, Jiang X, Wang P, Zhang J Comput Struct Biotechnol J. 2022; 20:2986-3003.
PMID: 35782737 PMC: 9218169. DOI: 10.1016/j.csbj.2022.06.015.
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing.
Zhang H, Sun R, Fei J, Chen H, Lu D Int J Mol Sci. 2022; 23(11).
PMID: 35682629 PMC: 9180235. DOI: 10.3390/ijms23115948.
Moassas F, Nweder M, Murad H BMC Pediatr. 2019; 19(1):61.
PMID: 30777047 PMC: 6378710. DOI: 10.1186/s12887-019-1435-5.